Lab-verified, documented raw materials designed for high-stability dietary and dermatological co-formulations.
Commercial formulations targeting the human microbiome require validated strain specificity. Alflorex probiotic formulations are centered around the clinically documented human-derived strain Bifidobacterium infantis 35624 (also classified as B. longum subsp. infantis). As global pharmaceutical brands, dietary supplement leaders, and clinical nutrition enterprises source raw materials, securing high-viability active pharmaceutical ingredients (API) or cGMP supplement grades presents steep bioprocessing hurdles. Le-Nutra bridges high-yield precision fermentation with pharmaceutical-grade downstream stabilization, delivering tailored OEM/ODM solutions characterized by complete genomic fingerprinting, validated gastrointestinal transit resilience, and certified microencapsulation architecture.
Global pharmaceutical brands require batch-to-batch guarantee exceeding 1.0 × 10¹¹ CFU/g at release, with strictly mapped shelf-life decay curves under accelerated climatic conditions (Zone IVb testing: 30°C / 75% RH).
Preventing microbial drift during successive sub-culturing runs. Modern procurement teams enforce whole-genome sequencing (WGS) and multi-locus sequence typing (MLST) to verify strain identity against original therapeutic baselines.
Demand is surging for synbiotic matrices where Bifidobacteria live harmoniously with clean-label vegetal proteins, hydrolyzed peptides, and standardized botanical actives without triggering premature microbial degradation.
Addressing the critical supply gaps in global therapeutic probiotic manufacturing through integrated biotechnology.
Bifidobacteria represent strict anaerobes requiring oxygen-depleted, high-nitrogen growth mediums. Our specialized multi-stage 50m³ bioreactors maintain strictly regulated redox potentials (Eh < -200 mV) alongside computer-controlled pH feeding, ensuring maximum cell density without metabolic shock.
Cell integrity easily collapses during lyophilization. We apply a patented natural matrix combining hydrolyzed plant proteins and specific oligosaccharides. This shields the bacterial cell wall against intracellular ice crystallization and acidic stomach fluids (pH 1.5–2.0), releasing active colonies intact within the ileum.
The future of gut axis modulation relies on targeted delivery systems. By coupling stabilized B. longum derivatives with clean botanical extracts (e.g., standard rosmarinic acid, apigenin, polyphenols) and short-chain bioactive plant peptides, we enable next-generation formulas that simultaneously balance mucosal barrier integrity and calm systemic inflammatory pathways.
Navigating global nutraceutical import standards with rigorous chemical, heavy-metal, and microbiological validation dossiers.
Complete 21 CFR Part 111 compliance. Complete New Dietary Ingredient (NDI) or self-affirmed GRAS documentation packs, batch-specific heavy metals (ICP-MS testing for Pb, As, Cd, Hg < 0.1 ppm), and USP microbial limits.
Strict Qualified Presumption of Safety (QPS) status alignment. Guaranteed non-GMO verified origin, fully compliant with EC Regulation 1829/2003, absence of animal allergens, and complete clean-room air filtration traceability.
Full Halal (MUI/JAKIM compliant) and Kosher certifications. Advanced moisture-impervious packaging specifically configured for high heat and humidity supply chain conditions encountered throughout Southeast Asia.
Dedicated enterprise technical response within 24 hours (UTC+8), rapid cold-chain air logistics, pre-shipment testing via independent ISO 17025 accredited third-party laboratories, and comprehensive customs clearing dossiers.
In-depth responses covering bacterial specifications, stability kinetics, encapsulation, and contract OEM production.
Our microbial fermentation platform cultivates Bifidobacterium longum subsp. infantis strains genetically mapped to deliver identical phenotypic properties: specific surface exopolysaccharide (EPS) architecture that avoids triggering pro-inflammatory NF-κB pathways, documented relief for irritable bowel symptom clusters, and superior enteric mucus adhesion.
We deploy lipid-polysaccharide dual-coating cryoprotection. This proprietary matrix seals lyophilized cells against atmospheric moisture and ambient oxidative breakdown, permitting room-temperature stability (25°C at 60% RH) for up to 24 months when packaged in high-barrier Alu-Alu or desiccant-lined HDPE bottles.
Yes. Le-Nutra specializes in integrated bio-active manufacturing. Our engineers custom blend Bifidobacterium strains with low-moisture vegetal proteins (pea, rice), hydrolyzed peptides, and standardized botanical extracts (e.g., chamomile, apigenin, lemon balm), ensuring zero premature water migration or cell death.
Standard raw powder MOQ begins at 10 kg, with full contract finished dosage (capsules, stick packs, sachets) starting at 100,000 units. Every batch is supplied with an exhaustive CoA, flow cytometry viability report, heavy metals, microbial limits, strain identification by PCR/16S rRNA, and allergen declarations.
Pharmaceutical, nutraceutical, and cosmetic raw materials engineered for maximum bioavailability and product stability.
Typical reply within one business day (UTC+8).
[email protected] +86-29-86518603 Request a Catalog Contact us